Case Report: Exchange transfusion for hemolytic anemia and acute kidney injury associated with hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin in a patient with hepatocellular carcinoma - Report - MDSpire
Advertisement
Case Report: Exchange transfusion for hemolytic anemia and acute kidney injury associated with hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin in a patient with hepatocellular carcinoma
Clinical Report: Management of Hemolytic Anemia and Acute Kidney Injury
Overview
This case report details a 55-year-old male with hepatocellular carcinoma who developed severe hemolytic anemia and acute kidney injury following hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin.
Background
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality globally, and hepatic arterial infusion chemotherapy (HAIC) with raltitrexed and oxaliplatin is emerging as a promising treatment. However, oxaliplatin is associated with severe adverse reactions, including hemolytic anemia and acute kidney injury, which necessitate careful management strategies.
Data Highlights
No numerical data or trial data was provided in the article.
Key Findings
Oxaliplatin can induce severe hemolytic anemia and acute kidney injury in patients with HCC.
The patient underwent two personalized sessions of exchange transfusion for management.
Artificial liver support therapy was utilized alongside exchange transfusion.
Prior to this treatment, the patient had not received any oxaliplatin-containing regimen.
Clinical Implications
Healthcare professionals should be aware of the potential for severe adverse reactions, such as hemolytic anemia and acute kidney injury, in patients receiving oxaliplatin as part of HAIC for HCC.
Conclusion
This case highlights the occurrence of complications in patients undergoing HAIC with oxaliplatin.
